(0.01%) 5 470.06 points
(-0.01%) 39 109 points
(0.29%) 17 768 points
(-0.53%) $80.40
(-4.06%) $2.64
(-0.85%) $2 311.00
(-0.05%) $28.86
(2.29%) $1 009.00
(0.28%) $0.936
(0.65%) $10.67
(0.47%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye...
Stats | |
---|---|
Today's Volume | 831 |
Average Volume | 38 046 |
Market Cap | 487.97M |
EPS | $-0.440 ( Q1 | 2024-05-08 ) |
Next earnings date | ( $-0.410 ) 2024-09-03 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
65.01 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.103 (0.88%) |
Oculis Holding AG Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Oculis Holding AG Financials
Annual | 2023 |
Revenue: | $883 000 |
Gross Profit: | $-28.36M (-3 212.23 %) |
EPS: | $-2.97 |
FY | 2023 |
Revenue: | $883 000 |
Gross Profit: | $-28.36M (-3 212.23 %) |
EPS: | $-2.97 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.180 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company\'s lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators